Vista Pharma.

Which are the latest news on Vista Pharma.?

Why is Vista Pharmaceuticals Ltd falling/rising?

As of 28-Jun, Vista Pharmaceuticals Ltd's stock price is at 6.95, reflecting a decline of -7.7%. The stock has underperformed significantly against the Sensex and is trading below its moving averages, indicating bearish sentiment.

As of 28-Jun, Vista Pharmaceuticals Ltd's stock price is falling, currently at 6.95, which reflects a change of -0.58 or -7.7%. This decline is part of a broader trend, as the stock has underperformed significantly compared to the benchmark Sensex, with a 1-week performance of -6.21% against -0.40% for the Sensex, and a year-to-date decline of -14.62% compared to -9.53% for the index.<BR><BR>Today's performance indicates that the stock has fallen after two consecutive days of gains, suggesting a trend reversal. Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals bearish sentiment. <BR><BR>Despite a notable increase in delivery volume by 185.21% on June 24, this has not translated into a positive price movement, as the stock has still underperformed its sector by -7.82%. Overall, these factors contribute to the ongoing decline in Vista Pharmaceuticals Ltd's stock price.

How big is Vista Pharma.?

As of 10th June, Vista Pharmaceuticals Ltd has a market capitalization of 43.00 Cr and reported Net Sales of 5.40 Cr, with a Net Profit loss of 12.06 Cr over the latest four quarters. Shareholder's Funds are 45.42 Cr and Total Assets are 55.92 Cr as of March 2025.

As of 10th June, Vista Pharmaceuticals Ltd has a market capitalization of 43.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vista Pharmaceuticals Ltd reported Net Sales of 5.40 Cr. However, the company experienced a loss of 12.06 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's Funds are reported at 45.42 Cr, while Total Assets amount to 55.92 Cr.

Who are in the management team of Vista Pharma.?

The management team of Vista Pharma includes Dhananjaya Alli (Chairman & Wholetime Director), Murali Meraga (Managing Director), and several Non-Executive Directors, including G Narendra and Umesh V Banakar. They oversee the company's strategic direction and management.

The management team of Vista Pharma includes the following individuals:<BR><BR>1. **Dhananjaya Alli** - Chairman & Wholetime Director<BR>2. **G Narendra** - Non-Executive & Independent Director<BR>3. **M H Rao** - Non-Executive & Non-Independent Director<BR>4. **Stanley Prabhakar Reddy** - Non-Executive & Non-Independent Director<BR>5. **Umesh V Banakar** - Non-Executive & Independent Director<BR>6. **Chakravarthula Divya Bhavani** - Non-Executive & Independent Director<BR>7. **Umakanth Katta** - Director<BR>8. **Divakar Reddy Yerrabommanahalli** - Director<BR>9. **Murali Meraga** - Managing Director<BR>10. **Pavan Sathvik Gilaka** - Whole Time Director (Operations)<BR><BR>This team is responsible for overseeing the strategic direction and management of the company.

Who are the peers of the Vista Pharma.?

Vista Pharma's peers include Vivo Bio Tech, Shelter Pharma, Kabra Drugs, Veerhealth Care, Vasundhara Rasy, Rajnish Wellness, Mangalam Drugs, Sandu Pharma, and ANG Lifesciences. Management risk varies from Below Average to Good among these companies, with Kabra Drugs showing the highest 1-year return at 86.81% and Vista Pharma at -33.75%.

Peers: The peers of Vista Pharma are Vivo Bio Tech, Shelter Pharma, Kabra Drugs, Veerhealth Care, Vasundhara Rasy., Rajnish Wellness, Mangalam Drugs, Sandu Pharma., and ANG Lifesciences.<BR><BR>Quality Snapshot: Below Average management risk is observed at Vivo Bio Tech, Kabra Drugs, Veerhealth Care, Rajnish Wellness, Mangalam Drugs, Sandu Pharma, and ANG Lifesciences, while Average management risk is found at Shelter Pharma and Rajnish Wellness. Good management risk is noted at Vasundhara Rasy. and the rest have Below Average management risk. Growth is Excellent at Kabra Drugs, Good at Shelter Pharma and Veerhealth Care, Average at Vasundhara Rasy., and Below Average at Vivo Bio Tech, Rajnish Wellness, Mangalam Drugs, Vista Pharma, Sandu Pharma, and ANG Lifesciences. Capital Structure is Excellent at Shelter Pharma, Good at Veerhealth Care and Sandu Pharma, and Below Average at Vivo Bio Tech, Kabra Drugs, Rajnish Wellness, Mangalam Drugs, Vista Pharma, ANG Lifesciences.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Rajnish Wellness has the lowest at -53.26%. Vista Pharma's 1-year return is -33.75%, which is better than Rajnish Wellness but worse than Kabra Drugs. Additionally, the six-month return is negative for Vivo Bio Tech, Shelter Pharma, Rajnish Wellness, Mangalam Drugs, and ANG Lifesciences.

What does Vista Pharma. do?

Vista Pharmaceuticals Ltd formulates pharmaceutical products in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company with a market cap of INR 43 Cr. As of March 2026, it reported a net profit loss of 6 Cr and has a debt-equity ratio of 0.27.

Overview:<BR>Vista Pharmaceuticals Ltd is engaged in the formulation of pharmaceutical products, primarily within the Pharmaceuticals & Biotechnology industry, and operates as a micro-cap company.<BR><BR>History:<BR>Vista Pharmaceuticals Limited was incorporated on January 25, 1991, and obtained its Certificate of Commencement of Business on February 7, 1991. The latest quarterly results reported are for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -6 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 43 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A (Loss Making)<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.27<BR>Return on Equity: -33.10%<BR>Price to Book: 1.24<BR><BR>Contact Details:<BR>Address: Plot No 10to14 16to20 APIIC, Industrial Estate Chotyal Nalgonda Telangana<BR>Phone: 91-09291015956<BR>Email: admin.hyd@vistapharmaceuticals.com<BR>Website: http://www.vistapharmaceuticals.com

Are Vista Pharmaceuticals Ltd latest results good or bad?

Vista Pharmaceuticals Ltd's latest results are concerning, with net sales dropping to ₹0.00 crore and a net loss of ₹5.86 crores, marking a 290.67% increase in losses year-over-year. The company is facing a severe operational crisis, indicating a bleak outlook for investors.

The latest results for Vista Pharmaceuticals Ltd are quite concerning. In Q4 FY26, the company reported net sales of ₹0.00 crore, marking a staggering 100% decline year-over-year. This represents a complete cessation of revenue generation, which is unprecedented for a company in the pharmaceutical sector. <BR><BR>Additionally, Vista Pharmaceuticals incurred a net loss of ₹5.86 crores in the same quarter, which is a dramatic increase of 290.67% compared to the previous year. The operating margin was effectively 0.0%, indicating that the company is not generating any profit from its operations. The return on equity (ROE) stands at a deeply negative -17.25%, highlighting significant value destruction for shareholders.<BR><BR>Overall, the financial performance indicates a severe operational crisis, with the absence of revenue and escalating losses suggesting that the company is in a critical state. Investors should be cautious, as the outlook appears bleak unless there are immediate and effective measures taken to resume operations.

When is the next results date for Vista Pharmaceuticals Ltd?

The next results date for Vista Pharmaceuticals Ltd is 29 May 2026.

The next results date for Vista Pharmaceuticals Ltd is scheduled for 29 May 2026.

Should I buy, sell or hold Vista Pharmaceuticals Ltd?

How has been the historical performance of Vista Pharma.?

Vista Pharma has experienced declining financial performance, with net sales dropping from 31.07 Cr in March 2019 to 10.07 Cr in March 2025, and consistent losses reflected in negative operating profits and increasing total liabilities. The company has struggled with cash flow from operations, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Vista Pharma shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods.<BR><BR>Breakdown:<BR>Vista Pharma's net sales peaked at 31.07 Cr in March 2019 but have since declined sharply, reaching only 10.07 Cr in March 2025. The total operating income followed a similar pattern, dropping from 22.76 Cr in March 2020 to 10.07 Cr in March 2025. The company has consistently reported negative operating profits, with the operating profit margin excluding other income deteriorating from 3.96% in March 2019 to -40.02% in March 2025. Profit before tax has also remained negative, with a loss of -5.29 Cr in March 2025 compared to a profit of 1.15 Cr in March 2019. The profit after tax reflects this trend, showing a loss of -4.65 Cr in March 2025, down from a profit of 0.94 Cr in March 2019. The company's total liabilities have increased from 50.74 Cr in March 2020 to 55.92 Cr in March 2025, while total assets have also risen from 50.74 Cr to 55.92 Cr in the same period. Cash flow from operating activities has remained negative, indicating ongoing challenges in generating cash from core operations. Overall, Vista Pharma's financial performance has shown a decline in revenue and profitability, with increasing losses over the years.

Is Vista Pharma. overvalued or undervalued?

As of April 25, 2023, Vista Pharma is considered risky and overvalued, with a PE ratio of -9.58 and an EV to EBITDA of -13.00%, significantly underperforming its peers and the Sensex.

As of 25 April 2023, Vista Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company is currently assessed as overvalued, with a PE ratio of -9.58, an EV to EBITDA of -13.00, and a ROCE of -15.40%. These ratios suggest that the company is struggling financially compared to its peers.<BR><BR>In comparison to its industry peers, Vista Pharma's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25, while Cipla is valued attractively with a PE of 22.99. The stark contrast in these ratios highlights Vista Pharma's challenges in generating positive earnings and returns. Additionally, the company's stock has underperformed against the Sensex over the past year, with a decline of 19.86% compared to the Sensex's gain of 7.60%, further reinforcing the notion that Vista Pharma is currently overvalued.

What is the technical trend for Vista Pharma.?

As of June 5, 2025, Vista Pharma's trend is mildly bearish due to daily moving averages and weekly RSI indicating bearish sentiment, despite some mixed signals from weekly MACD and Bollinger Bands.

As of 5 June 2025, the technical trend for Vista Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish sentiment and the weekly RSI showing bearish momentum. While the weekly MACD and KST are mildly bullish, the monthly indicators remain bearish, suggesting a lack of strong upward momentum. The Bollinger Bands on a weekly basis are bullish, but the overall monthly outlook is mildly bearish. The Dow Theory indicates a mildly bullish trend on the weekly chart, but with no clear trend on the monthly. Overall, the mixed signals across different time frames reflect a cautious outlook for Vista Pharma.

Who are the top shareholders of the Vista Pharma.?

The top shareholders of Vista Pharma include Murali Meraga with 14.62%, Vista Pharmaceuticals Inc. with 10.69%, and individual investors holding 33.62%. There are no foreign institutional investors or pledged promoter holdings.

The top shareholders of Vista Pharma include Vista Pharmaceuticals Inc., which holds 10.69%, and Murali Meraga, who is the highest public shareholder with 14.62%. Additionally, individual investors collectively hold 33.62% of the shares. There are also four mutual fund schemes with a minor holding of 0.02%, but no foreign institutional investors are involved. Notably, there are no pledged promoter holdings in the company.

Has Vista Pharma. declared dividend?

No Dividend History Available